Hereditary cancer syndromes as model systems for chemopreventive agent development.

Author(s): Walcott FL,  Patel J,  Lubet R,  Rodriguez L,  Calzone KA

Journal: Semin Oncol

Date: 2016 Feb

Major Program(s) or Research Group(s): CADRG, GOCRG

PubMed ID: 26970132

PMC ID: not available

Abstract: Research in chemoprevention has undergone a shift in emphasis for pragmatic reasons from large, phase III randomized studies to earlier phase studies focused on safety, mechanisms, and utilization of surrogate endpoints such as biomarkers instead of cancer incidence. This transition permits trials to be conducted in smaller populations and at substantially reduced costs while still yielding valuable information. This article will summarize some of the current chemoprevention challenges and the justification for the use of animal models to facilitate identification and testing of chemopreventive agents as illustrated though four inherited cancer syndromes. Preclinical models of inherited cancer syndromes serve as prototypical systems in which chemopreventive agents can be developed for ultimate application to both the sporadic and inherited cancer settings.